Imiquimod, Molluscum, and the Need for a Better “Best Pharmaceuticals for Children” Act

@article{Katz2013ImiquimodMA,
  title={Imiquimod, Molluscum, and the Need for a Better “Best Pharmaceuticals for Children” Act},
  author={Kenneth A Katz and Glenda L. Swetman},
  journal={Pediatrics},
  year={2013},
  volume={132},
  pages={1 - 3}
}
* Abbreviations: BPCA — : Best Pharmaceuticals for Children Act FDA — : Food and Drug Administration MC — : Molluscum contagiosum PI — : package insert RCT — : randomized controlled trial It was the best research Emily’s doctor had never heard about.* Emily was a delightful 6-year-old with molluscum contagiosum (MC). Characteristic dome-shaped umbilicated papules, some of them itchy, peppered her chest and buttocks. Emily had returned to the clinic, where one of us (KAK) saw her, after… 
Molluscum contagiosum in pediatric patients: to treat or not to treat? Could a personalized imiquimod regimen be the answer to the dilemma?
TLDR
Efficacy of this personalized treatment, scarce recurrence, absence of cicatricial sequelae and lack of necessity for deep sedation makes the use of Imiquimod the first line of treatment compared with other destructive treatments or with no-treatment at all.
Managing Molluscum with Imiquimod: Ignoring the Evidence
  • M. Levy
  • Medicine
    Pediatric dermatology
  • 2016
TLDR
The data do not appear to justify prescribing imiquimod for patients with MC based on outcomes or cost, and some resources do, however, continue to suggest the use of imiquIMod for special sites.
Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
TLDR
Topical imiquimod is a topically applicable Toll-like receptor (TLR)-7/8 agonist, which is capable of stimulating the innate cutaneous immunity and the cellular arm of the adaptive immune response and of exerting potent anti-viral, anti-tumor and immunoregulatory effects.
Imiquimod is not an effective drug for molluscum contagiosum.
  • K. Katz
  • Psychology
    The Lancet. Infectious diseases
  • 2014
Tratamento de Molusco Contagioso em crianças: uma revisão sistemática de literatura
TLDR
It is not possible to indicate the most eligible method based on the evidence found, therefore, treatment should be individualized.
Interventions for cutaneous molluscum contagiosum.
TLDR
This is an update of a Cochrane Review to assess the effects of specific treatments and management strategies, including waiting for natural resolution, for cutaneous, non-genital molluscum contagiosum in people without immune deficiency.
Molluscum contagiosum: the rise and fall of imiquimod
TLDR
The studies failed to demonstrate efficacy: one RCT, which enrolled 323 children, complete clearance at 18 weeks occurred in 24% of imiquimod-treated group and 26% of vehicle-treated Group.
The best pharmaceuticals for children-what can we do?
TLDR
A timeline of key laws, regulations and guidelines to improve pediatric clinical trials are shown and there is still a lack of Acts like BPCA and PREA in China.
Interventions for Nongenital Molluscum Contagiosum in Persons Without Immune Deficiency.
TLDR
Compared with placebo, imiquimod, 5%, cream was not more effective in clearing molluscum contagiosum and caused more local adverse effects, including application site reactions, in children aged 2 to 12 years.
A TREAT in store for those wishing to identify uncertainties in the treatment of severe childhood eczema
  • H. Williams
  • Medicine
    The British journal of dermatology
  • 2013
TLDR
The treatment survey, which excluded treatment of acute flares, showed large variations in practice in terms of firstand second-choice medications and how long they are used for, and suggests habit, tradition and strongly held views might also play a key role in explaining at least some of the variations observed.
...
1
2
3
4
...

References

SHOWING 1-10 OF 14 REFERENCES
Pharmacokinetics and Safety of Imiquimod 5% Cream in the Treatment of Molluscum Contagiosum in Children
Abstract:  Imiquimod cream 5%, a toll‐like receptor 7 agonist, induces α‐interferon upon topical application, prompting off‐label usage to treat children with molluscum contagiosum. We conducted an
Comparative Study on the Efficacy, Safety, and Acceptability of Imiquimod 5% Cream versus Cryotherapy for Molluscum Contagiosum in Children
TLDR
IMQ appears to be practically painless and more cosmetically accepted treatment when compared with cryotherapy, and may be the preferred treatment of MC in children especially with numerous small lesions.
Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
TLDR
The pediatric exclusivity program has been successful in encouraging drug studies in children, however, the dissemination of these results in the peer-reviewed literature is limited and mechanisms to more widely disperse this information through publication warrant further evaluation.
Diseases of the Skin: Clinical Dermatology
TLDR
This textbook is the sixth edition of the deservedly popular Andrews Diseases of the Skin and has been completely revised and rewritten by Anthony N. Domonkos, a longtime associate and colleague of George C. Andrews.
Economic return of clinical trials performed under the pediatric exclusivity program.
TLDR
The economic return for pediatric exclusivity is variable and as an incentive to complete much-needed clinical trials in children, Pediatrics Exclusivity can generate lucrative returns or produce more modest returns on investment.
Clinical Executive Summary [Imiquimod]. Available at: www.fda.gov/ downloads/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM162961.pdf
  • Accessed December
  • 2012
Copyright © 2013 by the American Academy of Pediatrics
  • 2013
Aldara (imiquimod) cream for topical use
  • Accessed January
  • 2007
...
1
2
...